Suganya Selvarajah

Suganya Selvarajah has worked in the field of biology since 2002. Suganya began their career as a Post Doctoral Fellow at The Scripps Research Institute, where they worked on an International Aids Vaccine Initiative (IAVI) funded project on HIV-1 Vaccine design. From 2008-2011, they were a Staff Scientist at UCSF and BSRI, where they were awarded a NIH R21 grant as Principal Investigator to study Biomarkers of Spontaneous HCV infection in plasma of HCV infected human cohorts with known outcome of infection. Suganya also conducted research on Chikungunya virus and established in vitro and in vivo assays for inhibiting virus replication. In 2011, they worked as a Consultant at Novartis. From 2012-2019, they were the Director-Head of Virology and Neurobiology at Prosetta Corporation, where they developed small-molecule inhibitors of host protein targets for respiratory viruses such as FLUV, RSV, Coronavirus as well as CNS program focused on ALS and PD therapeutics. Suganya also established and directed the use of cellular assays for screening small-molecule modulators following virus infection or oxidative stress response. In 2019, they became the Head of Immunology, Research and Development at ARAVASC, INC. and the Director of Biology at Attralus.

Suganya Selvarajah received a Doctor of Philosophy (Ph.D.) in Virology and Immunology from The University of Edinburgh.